Funding Opportunity RFA-CA-23-005 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

Funding Opportunity RFA-CA-23-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Funding Opportunity RFA-CA-23-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Funding Opportunity RFA-CA-23-008 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U54 Resource-Related Research Projects proposing to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Funding Opportunity RFA-CA-23-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI P01 program projects. The applicants should propose to expand upon original research question(s) from specific projects or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Funding Opportunity RFA-OD-23-005 from the NIH Guide for Grants and Contracts. This FOA announces the renewal of the NIH Research Evaluation and Commercialization Hub (REACH) program, established to facilitate and accelerate the translation of academic biomedical discoveries into products that improve patient care and public health. Through this program, NIH will provide the qualifying institutions with the funds to seed the creation of academic entrepreneurship Hubs. Hubs will be responsible for providing innovators with both the initial investment and resources to support the proof-of-concept work and the mentorship in product development and commercialization needed to develop high priority technologies within the NIHs mission. Funded Hubs are intended to work as a consortium to enable: (1) the infrastructure for identifying the most promising technologies, (2) funding for product definition studies (e.g. feasibility studies, prototype development, proof-of-concept studies) provided to individual researchers, (3) access to resources and expertise in areas required for early stage technology development (including scientific, regulatory, reimbursement, business, legal, and project management), and (4) skills development and hands-on experience in entrepreneurship. Establishing public-private partnerships and providing additional non-federal funds will be critical for success.

Notice NOT-NR-23-005 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-007 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Notice NOT-NR-23-004 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-23-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this FOA are meant to incentivize independent validation and accelerate the adoption of these emerging technologies by appropriate research communities.As a component of the NCI IMAT program, this FOA aims to promote interdisciplinary collaboration in the development of innovative tools and methods that enable cancer research and accelerate scientific discovery.

Notice NOT-NS-23-050 from the NIH Guide for Grants and Contracts

Notice NOT-NS-23-049 from the NIH Guide for Grants and Contracts

Notice NOT-DK-23-004 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-047 from the NIH Guide for Grants and Contracts

Notice NOT-AG-22-048 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-025 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-026 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-027 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-028 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-036 from the NIH Guide for Grants and Contracts